Fig 2: ROC curves of renalase and evaluated biomarkers for the prediction of ischemia in the total heart failure group. The curves should be interpreted with regard to Table 4. AUCs: BNP (0.837), sST2 (0.712), renalase (0.753), galectin-3 (0.726), syndecan-1 (0.709), cystatin C (0.704), GDF-15 (0.735). ROC, receiver operating characteristic; AUC, area under the curve; BNP, brain natriuretic peptide; sST2, soluble source of tumorigenicity 2; GDF-15, growth differentiation factor 15.

Fig 3: Echocardiography and cardiac remodeling. (A) Representative echocardiography in the three groups; LVIDd and LVIDs are shown in white lines. (B) Representative Masson’s trichrome in the ventricle of each group. The collagen fibers were stained in blue. (C) Quantitative analysis of Masson’s trichrome in each group. (D) and (E) Serum NE and BNP concentrations in each group. (F) and (G) %LVEF and %LVFS in each group. (H) and (I) LVIDs and LVIDd in each group. (J) and (K) LVPWs and LVPWd in each group. * p < 0.05 vs. the control group, ** p < 0.01 vs. the control group. # p < 0.05 vs. the METH group, ## p < 0.01 vs. the METH group. METH, methamphetamine; DAPA, dapagliflozin; LVEF, left ventricular ejection fraction; LVFS, left ventricular fraction shortening; LVIDd, left ventricular internal diameter at end-diastole; LVIDs, left ventricular internal diameter at end-systolic; LVPWd, left ventricular posterior wall thickness at end diastole; LVPWs, left ventricular posterior wall thickness at end systole; NE, noradrenaline; BNP, B-type natriuretic peptide.